Similarly, Girault et al (2003) found that DNMT3b overexpression was associated with a short relapse-free survival duration in a subgroup of breast cancer patients, and Wang et al (2004) demonstrated that increased DNMT3b promoter activity (resulting from a C-to-T polymorphism) led to lower survival duration in patients with SQLC of the head and neck. This evidence concerns the gene DNMT3B and breast carcinoma.